During the past decade, Brain Matters Research conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 33 clinical trials were completed, i.e. on average, 56.9% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 22 clinical trials were completed. i.e. 81.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Brain Matters Research" #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Hoffmann-La Roche" with 9 trials sponsored, "Biogen" with 7 trials sponsored, "Eisai Inc." with 5 trials sponsored and "Genentech, Inc." with 5 trials sponsored. Other sponsors include 55 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Brain Matters Research" #1 collaborator was "National Institute on Aging (NIA)" with 6 trials as a collaborator, "Pfizer" with 4 trials as a collaborator, "Alzheimer's Therapeutic Research Institute" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator and "Alzheimer's Clinical Trials Consortium" with 2 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Brain Matters Research" are "Alzheimer's Disease" (45 trials), "Alzheimer Disease" (32 trials), "Mild Cognitive Impairment" (5 trials), "Dementia" (4 trials) and "Alzheimers Disease" (3 trials). Many other conditions were trialed in "Brain Matters Research" in a lesser frequency.

Most popular intervention types in "Brain Matters Research" are "Drug" (88 trials), "Other" (9 trials), "Biological" (6 trials), "Device" (2 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (55 trials), "Gantenerumab" (5 trials), "Aducanumab" (4 trials), "bapineuzumab" (4 trials) and "placebo" (4 trials). Other intervention names were less common.

The vast majority of trials in "Brain Matters Research" are 95 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Brain Matters Research". undefined are not yet recruiting, 12 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in Brain Matters Research, 1 suspended trials, and 29 terminated clinical trials to date.

Out of the total trials that were conducted in Brain Matters Research, 11 "Phase 1" clinical trials were conducted, 49 "Phase 2" clinical trials and 40 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".